Extended-Release Amantadine May Improve Levodopa Dyskinesia Control

VANCOUVER — An extended-release amantadine formulation reduced levodopa-induced dyskinesia in a phase III Parkinson’s disease trial from the drug’s developer, Adamas Pharmaceuticals.
Source: Caring for the Ages - Category: Health Management Authors: Source Type: news